Pharmexa grants Padre license to ImmunoVaccine for VacciMax vaccines

By Lisa Kerner

Charlotte, N.C., Aug. 24 - Pharmexa A/S said it entered into a license agreement giving ImmunoVaccine Technologies Inc. (IVT) non-exclusive rights to use its Padre family of proprietary synthetic molecules in combination with up to three targets for IVT's VacciMax vaccines.

Financial details of the agreement, which calls for up-front and future payments as well as royalties, were not disclosed.

Padre, acquired from IDM Pharma, is an integral component of some of Pharmexa's vaccines in cancer and infectious diseases.

Pharmexa is a pharmaceutical company based in Horsholm, Denmark.

IVT is a biotechnology company based in Halifax, N.S.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.